Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 101-105 , 15 November 2010

Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use

  • Young Dae Kim

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Jung Hwan Lee

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Yo Han Jung

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Hye Yeon Choi

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Chung Mo Nam

      Affiliations

    • Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Jae Hoon Yang

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Han Jin Cho

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Hyo Suk Nam

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Kyung-Yul Lee

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • ,
  • Ji Hoe Heo

      Affiliations

    • Department of Neurology, Severance Hospital Integrative Research Institute for Cerebral and Cardiovascular Diseases , Yonsei University College of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author. Department of Neurology, Yonsei University College of Medicine, 250 Seongsan-no, Seodaemoon-gu, Seoul, 120-752, Republic of Korea. Tel.: +82 2 2228 1605; fax: +82 2 393 0705.

Received 18 February 2010 ,Revised 26 July 2010 ,Accepted 29 July 2010.

References 

  1. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655–1711
  2. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):630S–669S
  3. The European Stroke Oraganisation (ESO) Executive Committee; ESO writing Committee . Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507
  4. Han SW, Nam HS, Kim SH, Lee JY, Lee KY, Heo JH. Frequency and significance of cardiac sources of embolism in the TOAST classification. Cerebrovasc Dis. 2007;24(5):463–468
  5. Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med. 2006;48(2):182–1899 e1.
  6. Rombouts EK, Rosendaal FR, van der Meer FJ. Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost. 2009;101(3):552–556
  7. De Keyser J, Gdovinova Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke. 2007;38(9):2612–2618
  8. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282(21):2003–2011
  9. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329
  10. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65(5):607–611
  11. Ay H, Arsava EM, Gungor L, Greer D, Singhal AB, Furie KL, et al. Admission international normalized ratio and acute infarct volume in ischemic stroke. Ann Neurol. 2008;64(5):499–506
  12. Lee KY, Kim DI, Kim SH, Lee SI, Chung HW, Shim YW, et al. Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am J Neuroradiol. 2004;25(9):1470–1475
  13. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35–41
  14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587
  15. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282
  16. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology. 2001;57(11):1993–1999
  17. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540–546
  18. Group TEAFTS. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med. 1995;333(1):5–10
  19. Stanley AG, Fletcher S, Tan A, Barnett DB. Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction?. Heart. 2006;92(8):1145–1146
  20. Linfante I, Reddy AS, Andreone V, Caplan LR, Selim M, Hirsch JA. Intra-arterial thrombolysis in patients treated with warfarin. Cerebrovasc Dis. 2005;19(2):133–135
  21. Del Pace S, Scheggi V. Acute ischaemic stroke treated with combined intra-arterial thrombolysis and intravenous tirofiban despite oral anticoagulant therapy at an international normalised ratio > or = 2.0. Intern Emerg Med. 2006;1(3):250–252
  22. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W, et al. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke. 2009;40(11):3547–3551
  23. Dowlatshahi D, Hakim A, Fang J, Sharma M. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network. Int J Stroke. 2009;4(5):328–334
  24. Prabhakaran S, Rivolta J, Vieira JR, Rincon F, Stillman J, Marshall RS, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010;67(5):559–563
  25. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39(8):2249–2256
  26. van Oostenbrugge RJ, Hupperts RM, Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry. 2006;77(3):375–377
  27. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29(1):4–11

PII: S0022-510X(10)00348-5

doi: 10.1016/j.jns.2010.07.025

Journal of the Neurological Sciences
Volume 298, Issue 1 , Pages 101-105 , 15 November 2010

Article Tools

* Image Usage & Resolution